Fabtech Technologies Peer Comparison

NSE: FABTECH | BSE: 544558

₹123.90

₹1.69 (1.38%)

As on 30-Oct-2026IST

Market cap

₹547 Cr

Revenue (TTM)

₹388 Cr

P/E Ratio

15.4

P/B Ratio

1.2

Div. Yield

0.5 %

Edit

	Fabtech Technologies	Indegene	Sanofi Consumer Healthcare India	Lyka Labs	Genomic Biotech
Market cap (₹ Cr)	547	14,164	7,911	278	15
Revenue (₹ Cr)	388	4,131	979	145	0
Net Profit (₹ Cr)	35.56	411.10	279.70	-4.90	--
Net Margin (%)	8.59	9.78	27.97	-3.31	-0.79
RoE (%)	6.94	13.13	76.43	-4.53	-0.03
Price to Earnings	15.35	34.45	28.28	--	--
Price-To-Book	1.25	4.22	18.64	2.91	3.74

Income Statement (₹ Cr)

	Fabtech Technologies	Indegene	Sanofi Consumer Healthcare India	Lyka Labs	Genomic Biotech
Operating Revenue	410.77	3,510.50	878.40	128.44	0.84
Total Income	431.33	3,582.50	896.80	131.94	0.85
Total Expenditure	374.67	2,891.50	569.40	131.93	0.40
EBITDA	36.11	619.00	309.00	-3.49	0.44
Depreciation	5.30	126.40	11.70	8.46	0.00
EBIT	30.80	492.60	297.30	-11.95	0.44
Interest	5.27	19.30	2.00	3.33	0.00
Other Income	20.56	72.00	18.40	3.50	0.00
Exceptional Items	1.77	-20.30	6.60	--	--
Profit before Tax	48.27	525.00	320.30	-11.78	0.44
Provision for Tax	9.92	123.90	80.20	-1.34	0.09
Profit after Tax	38.36	401.10	240.10	-10.44	0.36

	Fabtech Technologies	Indegene	Sanofi Consumer Healthcare India	Lyka Labs	Genomic Biotech
Shareholder's Funds	419.77	3,138.70	384.00	92.39	3.90
Minority Interest	0.00	--	--	-1.56	--
Non-Current Liabilities	23.22	318.60	229.90	29.81	0.00
Current Liabilities	244.03	1,086.20	128.40	53.90	0.46
Total Liabilities	690.89	4,620.30	750.80	174.54	4.36

	Fabtech Technologies	Indegene	Sanofi Consumer Healthcare India	Lyka Labs	Genomic Biotech
Non-Current Assets	127.78	1,925.10	248.00	111.26	1.73
Current Assets	553.60	2,618.40	494.30	63.28	2.62
Total Assets	690.89	4,620.30	750.80	174.54	4.36
Total Debt*	42.73	0.00	0.00	48.36	0.00
Net Current Assets	309.57	1,532.20	365.90	9.38	2.16
Contingent Liabilities	45.15	--	1.50	37.44	--

	Fabtech Technologies	Indegene	Sanofi Consumer Healthcare India	Lyka Labs	Genomic Biotech
Cash From Operating Activities	0.48	650.80	174.80	5.24	0.03
Cash Flow from Investing Activities	-112.31	-512.40	7.60	-9.41	0.01
Cash from Financing Activities	189.66	-82.60	-134.50	4.19	--
Net Cash Inflow / Outflow	77.83	55.80	47.90	0.02	0.04

	Fabtech Technologies	Indegene	Sanofi Consumer Healthcare India	Lyka Labs	Genomic Biotech
ROCE (%)	15.51	18.92	98.11	-5.96	11.87
ROE (%)	12.94	14.14	73.20	-10.64	9.57
ROA (%)	6.90	10.31	37.26	-5.95	8.20
EBIT Margin (%)	13.79	19.68	37.27	0.01	52.63
Net Margin (%)	8.89	11.20	26.77	-7.91	41.97
Cash Profit Margin (%)	10.63	15.03	27.35	-1.54	42.50

	Fabtech Technologies	Indegene	Sanofi Consumer Healthcare India	Lyka Labs	Genomic Biotech
Revenue Growth (%)	25.75	23.64	21.24	-7.26	411.25
EBIT Growth (%)	17.94	7.72	15.44	-99.94	2,529.91
Net Profit Growth (%)	-17.43	-1.38	32.65	-231.54	2,245.51
EPS Growth (%)	-39.83	-1.79	32.65	-225.21	2,245.67
Book Value Growth (%)	142.48	19.89	41.18	-11.84	10.05

	Fabtech Technologies	Indegene	Sanofi Consumer Healthcare India	Lyka Labs	Genomic Biotech
Price / Earnings	16.17	26.06	43.36	0.00	50.26
Price / Book Value	1.48	3.38	27.11	1.74	4.59
Dividend Yield (%)	0.43	0.52	1.66	0.00	0.00
EV/EBITDA	8.02	14.57	30.65	0.00	40.19
Market Cap (₹ Cr)	620.31	10,450.76	10,410.62	159.68	17.90

	Fabtech Technologies	Indegene	Sanofi Consumer Healthcare India	Lyka Labs	Genomic Biotech
Debt to Equity	0.10	0.00	0.00	0.53	0.00
Short term debt to equity ratio	0.10	--	--	0.21	--
Current Ratio	2.27	2.41	3.85	1.17	5.73
Quick Ratio	2.18	2.41	3.37	0.92	5.11
Interest Coverage	10.17	28.20	161.15	-2.54	2,845.31

	Fabtech Technologies	Indegene	Sanofi Consumer Healthcare India	Lyka Labs	Genomic Biotech
Debtors to sales (%)	58.80	27.97	3.37	27.28	262.40
Asset Turnover	0.74	0.90	1.43	0.73	0.19
Receivable days	174.27	90.10	8.58	110.99	1,026.01
Inventory Days	35.88	0.00	20.38	37.08	122.93
Payable days	181.60	--	118.89	115.42	554.30
Cash Conversion Cycle	28.56	--	-89.93	32.64	594.64

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.